Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors

References

• Dao MA, Pepper KA, Nolta JA. Long-term cytokine production from engineered primary human stromal cells influences human hematopoiesis in an in vivo xenograft model. Stem Cells 1997; 15:443-54; PMID:9402657; http://dx.doi.org/10.1002/stem.150443
   PubMed Web of Science ®Google Scholar
• Liu K, Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol 2001; 167:6356-65; PMID:11714800; http://dx.doi.org/10.4049/jimmunol.167.11.6356
   PubMed Web of Science ®Google Scholar
• Liu K, Rosenberg SA. Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J Immunother 2003; 26:190-201; PMID:12806273; http://dx.doi.org/10.1097/00002371-200305000-00003
   PubMed Web of Science ®Google Scholar
• Meyerrose T, Olson S, Pontow S, Kalomoiris S, Jung Y, Annett G, Bauer G, Nolta JA. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev 2010; 62:1167-74; PMID:20920540; http://dx.doi.org/10.1016/j.addr.2010.09.013
   PubMed Web of Science ®Google Scholar
• Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, Marshak DR, Flake AW. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6:1282-6; PMID:11062543; http://dx.doi.org/10.1038/81395
   PubMed Web of Science ®Google Scholar
• Sanz L, Compte M, Guijarro-Munoz I, Alvarez-Vallina L. Non-hematopoietic stem cells as factories for in vivo therapeutic protein production. Gene Ther 2012; 19:1-7; PMID:21562594; http://dx.doi.org/10.1038/gt.2011.68
   PubMed Web of Science ®Google Scholar
• Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014; 32:252-60; PMID:24561556; http://dx.doi.org/10.1038/nbt.2816
   PubMed Web of Science ®Google Scholar
• Roth JC, Curiel DT, Pereboeva L. Cell vehicle targeting strategies. Gene Ther 2008; 15:716-29; PMID:18369326; http://dx.doi.org/10.1038/gt.2008.38
   PubMed Web of Science ®Google Scholar
• Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012; 64:739-48; PMID:21740940; http://dx.doi.org/10.1016/j.addr.2011.06.010
   PubMed Web of Science ®Google Scholar
• Khorashadizadeh M, Soleimani M, Khanahmad H, Fallah A, Naderi M, Khorramizadeh M. Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle. Tumour Biol 2015; 36:4213-21; PMID:25586349; http://dx.doi.org/10.1007/s13277-015-3058-2
   PubMed Web of Science ®Google Scholar
• Dudek AZ. Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy. Transl Res 2010; 156:136-46; PMID:20801410; http://dx.doi.org/10.1016/j.trsl.2010.07.003
   PubMed Web of Science ®Google Scholar
• Lin RZ, Dreyzin A, Aamodt K, Li D, Jaminet SC, Dudley AC, Melero-Martin JM. Induction of erythropoiesis using human vascular networks genetically engineered for controlled erythropoietin release. Blood 2011; 118:5420-8; PMID:21937702; http://dx.doi.org/10.1182/blood-2011-08-372946
   PubMed Web of Science ®Google Scholar
• Compte M, Alonso-Camino V, Santos-Valle P, Cuesta AM, Sanchez-Martin D, Lopez MR, Vicario JL, Salas C, Sanz L, Alvarez-Vallina L. Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system. Gene Ther 2010; 17:745-51; PMID:20336155; http://dx.doi.org/10.1038/gt.2010.33
   PubMed Web of Science ®Google Scholar
• Neumann H. Microglia: a cellular vehicle for CNS gene therapy. J Clin Invest 2006; 116:2857-60; PMID:17080190; http://dx.doi.org/10.1172/JCI30230
   PubMed Web of Science ®Google Scholar
• Lee S, Margolin K. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep 2012; 14:468-74; PMID:22878966; http://dx.doi.org/10.1007/s11912-012-0257-5
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Slaney CY, Darcy PK. Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunol 2014; 3:e16; PMID:25505964; http://dx.doi.org/10.1038/cti.2014.7
   PubMedGoogle Scholar
• Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21:215-23; PMID:19327974; http://dx.doi.org/10.1016/j.coi.2009.02.009
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3:388-98; PMID:23550147; http://dx.doi.org/10.1158/2159-8290.CD-12-0548
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 2015; 21:914-21; PMID:26193344; http://dx.doi.org/10.1038/nm.3910
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li H, Yang J, Li L, Zhang B, Li J, Zheng J. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer. Curr Gene Ther 2013; 13:65-70; PMID:23256743; http://dx.doi.org/10.2174/156652313804806570
   PubMed Web of Science ®Google Scholar
• Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013; 39:49-60; PMID:23890063; http://dx.doi.org/10.1016/j.immuni.2013.07.002
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843-51; PMID:20179677; http://dx.doi.org/10.1038/mt.2010.24
   PubMed Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013; 36:133-51; PMID:23377668; http://dx.doi.org/10.1097/CJI.0b013e3182829903
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 122:863-71; PMID:23770775; http://dx.doi.org/10.1182/blood-2013-03-490565
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709-20; PMID:22160384; http://dx.doi.org/10.1182/blood-2011-10-384388
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177ra38; PMID:23515080; http://dx.doi.org/10.1126/scitranslmed.3005930
   PubMed Web of Science ®Google Scholar
• Phan GQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control 2013; 20:289-97; PMID:24077405
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer–what clinicians need to know. Nat Rev Clin Oncol 2011; 8:577-85; PMID:21808266; http://dx.doi.org/10.1038/nrclinonc.2011.116
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 2012; 33:579-89; PMID:22926201; http://dx.doi.org/10.1016/j.it.2012.07.004
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013; 39:61-73; PMID:23890064; http://dx.doi.org/10.1016/j.immuni.2013.07.005
   PubMed Web of Science ®Google Scholar
• Bouzin C, Brouet A, De Vriese J, Dewever J, Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol 2007; 178:1505-11; PMID:17237399; http://dx.doi.org/10.4049/jimmunol.178.3.1505
   PubMed Web of Science ®Google Scholar
• Franciszkiewicz K, Boissonnas A, Boutet M, Combadiere C, Mami-Chouaib F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 2012; 72:6325-32; PMID:23222302; http://dx.doi.org/10.1158/0008-5472.CAN-12-2027
   PubMed Web of Science ®Google Scholar
• Oelkrug C, Ramage JM. Enhancement of T cell recruitment and infiltration into tumours. Clin Exp Immunol 2014; 178:1-8; PMID:24828133; http://dx.doi.org/10.1111/cei.12382
   PubMed Web of Science ®Google Scholar
• Sata M, Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998; 4:415-20; PMID:9546786; http://dx.doi.org/10.1038/nm0498-415
   PubMed Web of Science ®Google Scholar
• Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, Greenfield EA, Liang SC, Sharpe AH, Lichtman AH et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 2003; 33:3117-26; PMID:14579280; http://dx.doi.org/10.1002/eji.200324270
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012; 2012:948098; PMID:22778768; http://dx.doi.org/10.1155/2012/948098
   PubMed Web of Science ®Google Scholar
• Ma Y, Shurin GV, Peiyuan Z, Shurin MR. Dendritic cells in the cancer microenvironment. J Cancer 2013; 4:36-44; PMID:23386903; http://dx.doi.org/10.7150/jca.5046
   PubMed Web of Science ®Google Scholar
• Burkholder B, Huang RY, Burgess R, Luo S, Jones VS, Zhang W, Lv ZQ, Gao CY, Wang BL, Zhang YM et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 2014; 1845:182-201; PMID:24440852; http://dx.doi.org/10.1016/j.bbcan.2014.01.004
   PubMed Web of Science ®Google Scholar
• Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14:e218–28; PMID:23639322; http://dx.doi.org/10.1016/S1470-2045(12)70582-X
   PubMedGoogle Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007; 110:2793-802; PMID:17638856; http://dx.doi.org/10.1182/blood-2007-02-072843
   PubMed Web of Science ®Google Scholar
• Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, Zheng Z, Shelton TE, Matsuda K, Robbins PF et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008; 19:496-510; PMID:18444786; http://dx.doi.org/10.1089/hum.2007.0171
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 2004; 101:1969-74; PMID:14762166; http://dx.doi.org/10.1073/pnas.0307298101
   PubMed Web of Science ®Google Scholar
• Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 2005; 175:7226-34; PMID:16301627; http://dx.doi.org/10.4049/jimmunol.175.11.7226
   PubMed Web of Science ®Google Scholar
• Hsu C, Jones SA, Cohen CJ, Zheng Z, Kerstann K, Zhou J, Robbins PF, Peng PD, Shen X, Gomes TJ et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 2007; 109:5168-77; PMID:17353346; http://dx.doi.org/10.1182/blood-2006-06-029173
   PubMed Web of Science ®Google Scholar
• Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010; 24:1160-70; PMID:20428207; http://dx.doi.org/10.1038/leu.2010.75
   PubMed Web of Science ®Google Scholar
• Wagner HJ, Bollard CM, Vigouroux S, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE, Rooney CM. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther 2004; 11:81-91; PMID:14685154; http://dx.doi.org/10.1038/sj.cgt.7700664
   PubMed Web of Science ®Google Scholar
• Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010; 70:6725-34; PMID:20647327; http://dx.doi.org/10.1158/0008-5472.CAN-10-0735
   PubMed Web of Science ®Google Scholar
• Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, Rosenberg SA. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012; 18:1672-83; PMID:22291136; http://dx.doi.org/10.1158/1078-0432.CCR-11-3050
   PubMed Web of Science ®Google Scholar
• Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 2011; 19:751-9; PMID:21285960; http://dx.doi.org/10.1038/mt.2010.313
   PubMed Web of Science ®Google Scholar
• Zhang L, Feldman SA, Zheng Z, Chinnasamy N, Xu H, Nahvi AV, Dudley ME, Rosenberg SA, Morgan RA. Evaluation of gamma-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. J Immunother 2012; 35:430-9; PMID:22576348; http://dx.doi.org/10.1097/CJI.0b013e31825898e8
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119:4133-41; PMID:22354001; http://dx.doi.org/10.1182/blood-2011-12-400044
   PubMed Web of Science ®Google Scholar
• Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors. Oncoimmunology 2015; 4:e994446; PMID:25949921; http://dx.doi.org/10.4161/2162402X.2014.994446
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, Brentjens RJ. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia 2015; 29:415-22; PMID:25005243; http://dx.doi.org/10.1038/leu.2014.215
   PubMed Web of Science ®Google Scholar
• Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 2015; 21:2278-88; PMID:25695689; http://dx.doi.org/10.1158/1078-0432.CCR-14-2085
   PubMed Web of Science ®Google Scholar
• Markley JC, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 2010; 115:3508-19; PMID:20190192; http://dx.doi.org/10.1182/blood-2009-09-241398
   PubMed Web of Science ®Google Scholar
• Compte M, Blanco B, Serrano F, Cuesta AM, Sanz L, Bernad A, Holliger P, Alvarez-Vallina L. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007; 14:380-8; PMID:17218946; http://dx.doi.org/10.1038/sj.cgt.7701021
   PubMed Web of Science ®Google Scholar
• Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C, Song XT, Gottschalk S. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 2015; 23:171-8; PMID:25142939; http://dx.doi.org/10.1038/mt.2014.156
   PubMed Web of Science ®Google Scholar
• Rahir G, Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother 2012; 61:751-9; PMID:22488275; http://dx.doi.org/10.1007/s00262-012-1253-1
   PubMed Web of Science ®Google Scholar
• Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 2006; 213:48-65; PMID:16972896; http://dx.doi.org/10.1111/j.1600-065X.2006.00441.x
   PubMed Web of Science ®Google Scholar
• Fijak M, Meinhardt A. The testis in immune privilege. Immunol Rev 2006; 213:66-81; PMID:16972897; http://dx.doi.org/10.1111/j.1600-065X.2006.00438.x
   PubMed Web of Science ®Google Scholar
• Cose S. T-cell migration: a naive paradigm? Immunology 2007; 120:1-7; PMID:17233737; http://dx.doi.org/10.1111/j.1365-2567.2006.02511.x
   PubMed Web of Science ®Google Scholar
• Kratz F, Warnecke A. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. J Control Release 2012; 164:221-35; PMID:22705248; http://dx.doi.org/10.1016/j.jconrel.2012.05.045
   PubMed Web of Science ®Google Scholar
• Hooijberg E, Bakker AQ, Ruizendaal JJ, Spits H. NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. Blood 2000; 96:459-66; PMID:10887106
   PubMed Web of Science ®Google Scholar
• Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94:902-8; PMID:10419880
   PubMed Web of Science ®Google Scholar
• Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberte RJ, Ryan JL, Zonno K, Rook AH. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 2006; 55:807-13; PMID:17052486; PMID:12391195; http://dx.doi.org/10.1016/j.jaad.2006.06.038
   PubMed Web of Science ®Google Scholar
• Almeida AR, Legrand N, Papiernik M, Freitas AA. Homeostasis of peripheral CD4+ T cells: IL-2R α and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol 2002; 169:4850-60; PMID:12391195; http://dx.doi.org/10.4049/jimmunol.169.9.4850
   PubMed Web of Science ®Google Scholar
• Koneru M, O'Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 2015; 13:102; PMID:25890361; http://dx.doi.org/10.1186/s12967-015-0460-x
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA, Murphy PM, Hwu P. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 2002; 13:1971-80; PMID:12427307; http://dx.doi.org/10.1089/10430340260355374
   PubMed Web of Science ®Google Scholar
• Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 2010; 33:780-8; PMID:20842059; http://dx.doi.org/10.1097/CJI.0b013e3181ee6675
   PubMed Web of Science ®Google Scholar
• Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor. J Immunother 2008; 31:500-5; PMID:18463534; http://dx.doi.org/10.1097/CJI.0b013e318177092b
   PubMed Web of Science ®Google Scholar
• Bendle GM, Linnemann C, Bies L, Song JY, Schumacher TN. Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol 2013; 191:3232-9; PMID:23940272; http://dx.doi.org/10.4049/jimmunol.1301270
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19851315; http://dx.doi.org/10.1038/nrc2734
   PubMed Web of Science ®Google Scholar
• Rebe C, Vegran F, Berger H, Ghiringhelli F. STAT3 activation: A key factor in tumor immunoescape. Jak-Stat 2013; 2:e23010; PMID:24058791; http://dx.doi.org/10.4161/jkst.23010
   PubMedGoogle Scholar
• Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012; 30:1005-14; PMID:22355058; http://dx.doi.org/10.1200/JCO.2010.31.8907
   PubMed Web of Science ®Google Scholar
• Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol 2013; 93:847-63; PMID:23475577; http://dx.doi.org/10.1189/jlb.1012501
   PubMed Web of Science ®Google Scholar
• Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Rapoport AP, Ostrand-Rosenberg S, Davila E. TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. Cancer Res 2015; 75:1959-71; PMID:25795705; http://dx.doi.org/10.1158/0008-5472.CAN-14-2467
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365:1673-83; PMID:22047558; http://dx.doi.org/10.1056/NEJMoa1106152
   PubMed Web of Science ®Google Scholar
• Bae HD, Lee K. On employing a translationally controlled tumor protein-derived protein transduction domain analog for transmucosal delivery of drugs. J Control Release 2013; 170:358-64; PMID:23791976; http://dx.doi.org/10.1016/j.jconrel.2013.06.010
   PubMed Web of Science ®Google Scholar